CMR, disappearance of all 18F-FDG-avid lesions: PMD, unequivocal progression of 18F-FDG-avid nontarget lesions or appearance of new 18F-FDG-avid lesions typical of cancer; non-PMD: persistence of one or more nontarget lesions or tumor markers above normal limits.